Aethlon Medical Revenue 2010-2023 | AEMD

Aethlon Medical revenue from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Aethlon Medical Annual Revenue
(Millions of US $)
2023 $1
2022 $0
2021 $1
2020 $1
2019 $0
2018 $0
2017 $0
2016 $1
2015 $1
2014 $2
2013 $1
2012 $1
2011 $
2010 $
2009 $
Aethlon Medical Quarterly Revenue
(Millions of US $)
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $1
2020-09-30
2020-06-30
2020-03-31 $0
2019-12-31 $0
2019-09-30
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30
2017-06-30
2017-03-31 $0
2016-12-31
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $1
2013-12-31 $0
2013-09-30 $1
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $1
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.004B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $487.657B 20.99
Cigna Group (CI) United States $100.732B 13.71
Humana (HUM) United States $43.786B 13.96
Centene (CNC) United States $42.907B 12.05
Molina Healthcare (MOH) United States $23.755B 19.47
Select Medical Holdings (SEM) United States $3.654B 14.32
Joint (JYNT) United States $0.145B 75.62